Aimmune Therapeutics, Inc. announced that Aimmune's Chief Operating Officer Howard Raff will retire from his position on October 31, 2015. Dr. Raff will become a consultant for Aimmune, working on developing future product opportunities for food allergens.
Aimmune Therapeutics, Inc.
Equities
AIMT
US00900T1079
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+18.15% | 124B | |
+18.02% | 111B | |
-12.75% | 23.17B | |
+5.07% | 22.94B | |
-39.94% | 17.42B | |
-9.86% | 17.42B | |
-14.97% | 16.9B | |
+2.80% | 13.71B | |
+27.39% | 11.82B |